Pathfinder Medical Secures £13.5k in Latest Funding Allotment

London-based medical device developer Stent Tek Limited, which operates under the trading name Pathfinder Medical, has registered a new funding allotment of £13.5k. The transaction, classified as a pre-seed round in recent filings, brings the company to an estimated post-money valuation of £5.3m.

Founded in October 2014 by Sorin Popa and Robert Dickinson, Pathfinder Medical emerged from research conducted at Imperial College London. The company specialises in developing electronic guidance systems for endovascular surgery. Its flagship technology, the ePath catheter system, is designed to help clinicians connect blood vessels in a minimally invasive manner.

The primary clinical application for Pathfinder Medical's technology is in the treatment of patients requiring dialysis. Traditionally, preparing a patient for dialysis involves open surgery to create a fistula, a robust connection between an artery and a vein that enables the effective filtering of blood. This surgical procedure can be time-consuming to heal and carries a risk of failure. Pathfinder Medical solves this problem by using electric fields to guide and align catheters, allowing clinicians to make these vascular connections from inside the body without the need for open surgery. This approach aims to reduce surgical trauma, improve patient outcomes, and lower costs for healthcare providers.

The latest funding filing, dated March 10, 2026, details an allotment from February 17, 2026. The £13.5k raise is notably small for a company of this maturity and is classified as a pre-seed allotment. This modest capital injection contrasts with the company's historical funding activity. In January 2022, Pathfinder Medical secured an £8.5m investment round led by the Business Growth Fund and Parkwalk, with participation from Deepbridge Capital. Given the £5.3m estimated post-money valuation attached to this new £13.5k filing, the transaction likely represents an administrative share issuance, a minor top-up from an existing backer, or the exercise of earlier options rather than a primary institutional round.

Financially, the company operates with a highly lean core structure. Recent corporate accounts report an average employee headcount of less than one full-time equivalent, while professional networking profiles indicate a single primary employee linked to its Stevenage operations base. This reflects a business model that likely relies heavily on external clinical partnerships, outsourced manufacturing, and specialist contractors to advance its medical devices.

The UK funding landscape for health tech and medical hardware remains highly selective. While software-based health platforms often attract rapid early-stage capital, hardware and medical device companies like Pathfinder Medical face longer development cycles and stringent regulatory hurdles. Consequently, funding in this sub-sector tends to be milestone-driven, with capital unlocked as companies progress through clinical trials and secure regulatory approvals. Pathfinder Medical's continued corporate activity highlights the ongoing development required to bring complex, minimally invasive surgical technologies to the global market.